Soligenix (SNGX) Research & Development (2010 - 2026)
Soligenix's (SNGX) quarterly Research & Development came in at $1.8 million in Q1 2026, down 8.21% YoY from $1.9 million in Q1 2025, and down 21.94% on a QoQ basis from $2.3 million in Q4 2025.
Soligenix (SNGX) Research & Development (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Research & Development data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Research & Development fell 8.21% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 20.69% YoY) and the FY2025 annual result came in at $7.5 million, up 43.31% from the prior year.
- Research & Development eased to $1.8 million in Q1 2026, from $2.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.7 million in Q4 2024 to a low of $501158.0 in Q2 2024.
- A 5-year average of $1.5 million and a median of $1.7 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 67.02% — and 2024, when it soared 241.94%.
- Tracing SNGX's Research & Development over 5 years: stood at $2.4 million in 2022, then plunged by 67.02% to $777534.0 in 2023, then soared by 241.94% to $2.7 million in 2024, then decreased by 14.12% to $2.3 million in 2025, then retreated by 21.94% to $1.8 million in 2026.
- The last three Research & Development figures came in at $1.8 million (Q1 2026), $2.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | Soligenix | 6.21 Mn | 6.21 Mn | - | 974,091.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 974,091.00 |
| Mar 31, 2026 | 1.78 Mn |
| Dec 31, 2025 | 2.28 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Sep 30, 2024 | 968,689.00 |
| Jun 30, 2024 | 501,158.00 |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 777,534.00 |
| Sep 30, 2023 | 826,015.00 |
| Jun 30, 2023 | 762,699.00 |
| Mar 31, 2023 | 946,451.00 |
| Dec 31, 2022 | 2.36 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 2.05 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 2.70 Mn |
| Sep 30, 2021 | 2.24 Mn |